NASDAQ:TORC - resTORbio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.70 +0.07 (+0.55 %) (As of 12/12/2018 09:33 AM ET)Previous Close$12.63Today's Range$12.70 - $12.7052-Week Range$7.55 - $21.10Volume552 shsAverage Volume183,239 shsMarket Capitalization$338.35 millionP/E Ratio-1.51Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts. Receive TORC News and Ratings via Email Sign-up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TORC Previous Symbol CUSIPN/A Webwww.restorbio.com Phone857-315-5521 Debt Debt-to-Equity RatioN/A Current Ratio14.52 Quick Ratio14.52 Price-To-Earnings Trailing P/E Ratio-1.51 Forward P/E Ratio-7.43 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.17) per share Price / Book-10.85 Profitability EPS (Most Recent Fiscal Year)($8.42) Net Income$-33,770,000.00 Net MarginsN/A Return on Equity-67.59% Return on Assets-50.08% Miscellaneous Employees7 Outstanding Shares28,060,000Market Cap$338.35 million OptionableNot Optionable resTORbio (NASDAQ:TORC) Frequently Asked Questions What is resTORbio's stock symbol? resTORbio trades on the NASDAQ under the ticker symbol "TORC." How were resTORbio's earnings last quarter? resTORbio, Inc. (NASDAQ:TORC) announced its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.21. View resTORbio's Earnings History. When is resTORbio's next earnings date? resTORbio is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for resTORbio. What price target have analysts set for TORC? 4 equities research analysts have issued 1 year target prices for resTORbio's stock. Their predictions range from $23.00 to $36.00. On average, they expect resTORbio's stock price to reach $29.25 in the next year. This suggests a possible upside of 130.3% from the stock's current price. View Analyst Price Targets for resTORbio. What is the consensus analysts' recommendation for resTORbio? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for resTORbio. Has resTORbio been receiving favorable news coverage? News articles about TORC stock have been trending positive on Wednesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. resTORbio earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. Who are some of resTORbio's key competitors? Some companies that are related to resTORbio include Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Spectrum Pharmaceuticals (SPPI), Mirati Therapeutics (MRTX), Tricida (TCDA), Myovant Sciences (MYOV), Insmed (INSM), G1 Therapeutics (GTHX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Clovis Oncology (CLVS), Uniqure (QURE), TherapeuticsMD (TXMD), Kiniksa Pharmaceuticals (KNSA) and Deciphera Pharmaceuticals (DCPH). Who are resTORbio's key executives? resTORbio's management team includes the folowing people: Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 46)Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 59)Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 50)Ms. Jennifer Robinson, Sr. Director of Investor Relations & Corp. CommunicationDr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 68) When did resTORbio IPO? (TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are resTORbio's major shareholders? resTORbio's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (7.68%), Baillie Gifford & Co. (3.51%), Artal Group S.A. (1.78%), Segantii Capital Management Ltd (1.71%), BlackRock Inc. (1.68%) and Deltec Asset Management LLC (1.46%). Company insiders that own resTORbio stock include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Institutional Ownership Trends for resTORbio. Which major investors are selling resTORbio stock? TORC stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Artal Group S.A. and Virtus ETF Advisers LLC. View Insider Buying and Selling for resTORbio. Which major investors are buying resTORbio stock? TORC stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Segantii Capital Management Ltd, BlackRock Inc., Deltec Asset Management LLC, Baillie Gifford & Co., Schroder Investment Management Group, Alps Advisors Inc. and Vanguard Group Inc.. Company insiders that have bought resTORbio stock in the last two years include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Insider Buying and Selling for resTORbio. How do I buy shares of resTORbio? Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is resTORbio's stock price today? One share of TORC stock can currently be purchased for approximately $12.70. How big of a company is resTORbio? resTORbio has a market capitalization of $338.35 million. The company earns $-33,770,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis. resTORbio employs 7 workers across the globe. What is resTORbio's official website? The official website for resTORbio is http://www.restorbio.com. How can I contact resTORbio? resTORbio's mailing address is 500 BOYLSTON STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5521. MarketBeat Community Rating for resTORbio (NASDAQ TORC)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 49 (Vote Outperform)Underperform Votes: 45 (Vote Underperform)Total Votes: 94MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: What are defining characteristics of a correction?